The mechanism by which the high
bone mass (HBM)
mutation (G171V) of the Wnt coreceptor LRP5 regulates the canonical Wnt signaling was investigated. The
mutation was previously shown to reduce Dkk
protein-1-mediated
antagonism, suggesting that the first YWTD repeat domain where G171 is located may be responsible for Dkk
protein-mediated
antagonism. However, we found that the third YWTD repeat, but not the first repeat domain, is required for DKK1-mediated
antagonism. Instead, we found that the G171V
mutation disrupted the interaction of LRP5 with Mesd, a chaperon
protein for LRP5 / 6 that is required for the coreceptors' transport to
cell surfaces, resulting in less LRP5 molecules on the
cell surface. Although the reduction in the level of
cell surface LRP5 molecules led to a reduction in Wnt signaling in a paracrine paradigm, the mutation did not appear to affect the activity of coexpressed Wnt in an autocrine paradigm. Together with the observation that
osteoblast cells produce autocrine canonical Wnt, Wnt7b, and that osteocytes produce paracrine Dkk1, we believe that the G171V mutation may cause an increase in Wnt activity in osteoblasts by reducing the number of targets for paracrine Dkk1 to antagonize without affecting the activity of autocrine Wnt.